ArticleFrontiers in medicine2026
Case Report: A rare case of combined branch retinal vein occlusion and branch retinal artery occlusion.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Combined branch retinal artery and vein occlusion: a multimodal imaging insight.Eye (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Significance: The combination of branch retinal vein occlusion (BRVO) and branch retinal artery occlusion (BRAO) is extremely rare. At present, the pathogenic mechanism underlying the occurrence of combined BRVO and BRAO remains unclear. Prompt treatment of macular edema (ME) secondary to combined BRVO and BRAO with anti-vascular endothelial growth factor (anti-VEGF) therapy and laser photocoagulation can achieve a satisfactory prognosis. Purpose: This report presents a rare case of ME secondary to combined BRVO and BRAO treated with anti-VEGF agents and laser photocoagulation. Case report: A 59-year-old man presented with a 3-month history of blurred vision in the left eye. The patient had a 5-year history of diabetes and hypertension. On examination, the best-corrected visual acuity (BCVA) was 20/20 in the right eye and 20/125 in the left eye, and the intraocular pressure in both eyes was within the normal range. Slit lamp examination revealed unremarkable anterior segments in both eyes, except for lens opacity. According to the fundus examination findings, a diagnosis of ME secondary to combined BRVO and BRAO in the left eye was established. The central macular thickness (CMT) in the left eye was 302 μm. The patient subsequently underwent angiography-guided sectoral laser photocoagulation and received intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents in the left eye. After 3 months of treatment, the BCVA in the left eye improved to 20/40, the CMT decreased to 182 μm, and the intraretinal fluid was resolved. Thereafter, the patient did not return to the clinic for further ophthalmic examinations. Conclusion: Combined BRVO and BRAO is an uncommon and extremely rare retinopathy. Intravitreal injection of anti-VEGF drugs and laser photocoagulation are effective treatments for ME secondary to combined BRVO and BRAO. In addition, systemic evaluation and close monitoring of cardiovascular risk factors should not be overlooked.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.